SCYNEXIS, Inc. to Present at JMP Securities Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., June 18, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' President and Chief Executive Officer, will present at the 9^th Annual JMP Securities Healthcare Conference at the Westin Grand Central Hotel in New York City on Tuesday, June 24, 2014, at 3:00 p.m. ET.

A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.

CONTACT: Company
         Chuck Osborne
         Chief Financial Officer
         Tel: 919-544-8600
         E-mail: chuck.osborne@scynexis.com

         Investor/Media Relations
         Heather Savelle
         MacDougall Biomedical Communications
         Tel: 781-235-3060
         E-mail: hsavelle@macbiocom.com

Source: SCYNEXIS, Inc.

Released June 18, 2014